News

People in the United Kingdom (U.K.) with multiple sclerosis (MS) have an increased risk of vascular disease affecting the heart and brain that is not accounted for by traditional disease risk factors, a large, population-based study reports.  The study, “Evaluating the Risk of Macrovascular Events and…

Movements that are an act of “learning” motor tasks after lesions appear in the protective myelin sheath of neurons seem to induce both new and existing oligodendrocytes — the cells that make up myelin — to repair those lesions, a study in mice shows. Precisely timed rehabilitation programs and exercise may…

Biogen has released new data on several of its therapies for multiple sclerosis (MS), including Vumerity (diroximel fumarate), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). The data — six presentations — originally were to be presented at the 2020 annual conference of the American…

Glatopa, a generic form of Copaxone, is as effective as the brand-name medication in terms of disease outcomes and has similar healthcare-related costs in real-world use in patients with relapsing multiple sclerosis (MS), a new U.S. study suggests. Data also suggest a trend toward lower relapse rates with Glatopa…

People with multiple sclerosis (MS) and other neurological diseases have a significantly higher aluminum content in their brains than those with no known neurological impairment and no identifiable neurodegenerative disease, a recent study found. The research further supports a role of aluminum in the development of these brain conditions,…

In the brains of people with advanced multiple sclerosis (MS), memory immune cells reside in the brain tissue rather than entering through the bloodstream, a new study suggests. The study, “Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions,” was published…

Targeting the MOSPD2 protein may prevent immune cells known as monocytes from entering the central nervous system (CNS), which may significantly ease brain inflammation and myelin damage in multiple sclerosis (MS), a study in mice suggests. VBL Therapeutics, the company leading the study, has developed…

Healthcare providers should encourage everyone with multiple sclerosis (MS) to engage in regular exercise and keep physically active, new guidelines based on an expert panel convened by the National Multiple Sclerosis Society recommend. They also suggest different types of exercise applicable to people at varying levels of disability.

Supporting evidence that infection with Epstein-Barr virus (EBV) could be one of the root causes of multiple sclerosis (MS), a recent study found all of its 901 early disease patients carry antibodies against this virus, meaning that all are or have been exposed to it. The study, “…

Four weeks of mindfulness meditation helped to improve thinking skills and a sense of emotional balance in people with multiple sclerosis (MS), and to a greater extent than cognitive training given to a separate patient group, a pilot clinical trial reports.  These results were detailed in two studies,“…

People with progressive forms of multiple sclerosis (MS) have faster and disease-modifying therapy (DMT)-resistant retinal atrophy (thinning), compared to those with relapsing-remitting MS (RRMS), a study shows. Data also highlighted that the thickness of deeper layers of the retina could be used as potential biomarkers of neurodegeneration in…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Helius Medical Technologies’ portable neuromodulation stimulator (PoNS) for the treatment of walking impairments in multiple sclerosis (MS) patients. The device, which is meant to be used…

A patient registry of multiple sclerosis (MS) among veterans of the U.S. military has been created to allow for better clinical management of these people and to inform future research. The registry is described in the study “…

Neuroscientist Ian D. Duncan has been awarded the 2020 John Dystel Prize for Multiple Sclerosis Research for work that advanced understanding of how myelin, the protective sheath surrounding nerve cells, can be repaired in diseases like multiple sclerosis (MS). “Professor Duncan has made a series of critical research advances…

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to…

People with multiple sclerosis (MS) may not be at higher risk of developing a severe COVID-19 infection, according to preliminary data from patients in Italy. “At the moment, these results seem to be quite reassuring for most people with MS,” Marco Salvetti, MD, PhD, professor at Sapienza…

MMJ International Holdings announced that it has been given clearance to ship its cannabis-based products to the U.S. for use in future clinical trials of potential cannabis-based treatment for multiple sclerosis (MS) and Huntington’s disease. The process was facilitated by the U.S. Drug Enforcement Agency (DEA), which worked alongside…

A portable device that can quickly measure electrical activity in the brain and relay it to doctors via a smartphone app, called the Nurochek system, has been cleared by the United States Food and Drug Administration (FDA) for use as a medical device. Its developer, Headsafe, plans to it…

IC 100, a monoclonal antibody by ZyVersa Therapeutics that prevents the assembly of inflammasomes — a pro-inflammatory cellular complex — lessened inflammation and halted disease progression in multiple sclerosis (MS), a study of mice shows.xa The study, “IC100: a novel anti-ASC monoclonal antibody improves functional outcomes…

A high-dose chemotherapy combination given to wipe out the immune system before its rescue with autologous hematopoietic stem cell transplant (aHSCT) can cause “transient” damage to neurons and supporting cells of the central nervous system in people with aggressive multiple sclerosis (MS), a Canadian study reports. Nonetheless, its researchers believe…

People with relapsing multiple sclerosis (MS) being treated with Gilenya (fingolimod) for eight or more years show smaller increases in disability over 10 years than those using this treatment for a shorter time, a long-term follow-up study reports. Longer use of Gilenya also resulted in lesser disability progression,…

NurOwn, believed to have neuroprotective and repairing effects, may also be able to curb the damaging immune responses that contribute to multiple sclerosis (MS) progression, a recent study found. This newly identified potential may extend the benefits of this cell-based therapy, its researchers believe. The findings were to be presented…

Altered levels of molecules important for cell regulation — called microRNAs — have been found in specific immune cells isolated from the blood of people with multiple sclerosis (MS), a study reveals. These immune cells, called monocytes, transform into macrophage cells,…

COVID-19 infection in a multiple sclerosis (MS) patient being treated with Ocrevus (ocrelizumab) — an immunosuppressive therapy — was not associated with any serious complications, a case study reports. This finding supports current suggestions that immunosuppressive therapies, by dampening immune and inflammatory responses, may help to protect…

Belong.Life has launched a free and anonymous social network app to offer support for people with multiple sclerosis (MS), their caregivers, and healthcare professionals. The app is called BelongMS and is now available…

The U.S. Food and Drug Administration (FDA) has given final approval to Banner Life Sciences’ Bafiertam (monomethyl fumarate), a bioequivalent alternative to Biogen’s Tecfidera (dimethyl fumarate) to treat people with relapsing…

Pain appears to be more intense in people with neuromyelitis optica spectrum disorder (NMOSD) than those with multiple sclerosis (MS), while fatigue levels are comparable between the two disorders, a study reports. Its researchers also link certain types of central nervous system lesions to pain and fatigue in…

The investigational anti-CD20 antibody ublituximab effectively depletes B-cells in people with relapsing forms of multiple sclerosis (MS), reducing the appearance of brain lesions and the risk of relapses, a study into clinical trial results suggests. Findings further suggest that the…

The Multiple Sclerosis Society of Canada is launching a virtual effort that seeks to connect multiple sclerosis (MS) communities across the country and raise funds for research in observance of Multiple Sclerosis Awareness Month in Canada. As part of the initiative, called #WeChallengeMS, Canadian…

A new tiny sensor is able to detect antibodies against myelin, the protective coating of nerve cell axons whose destruction is a hallmark of multiple sclerosis (MS), potentially allowing for a diagnosis in early disease stages, researchers report. It also offers the possibility of distinguishing multiple sclerosis from neuromyelitis optica, a…